

# 2025-26 Seasonal Influenza Vaccine Dosage Chart

## Inactivated Influenza Vaccine, Adjuvanted, Trivalent (aIIV3)

Manufacturer <sup>1</sup>	Trade name	Age	Dose – Presentation <sup>2</sup>	Route
Seqirus	Fluad	65 years and older	0.5 mL – prefilled syringe	IM (intramuscular) <sup>3</sup>

## Recombinant Influenza Vaccine, Trivalent (RIV3)

Manufacturer	Trade name	Age	Dose – Presentation	Route
Sanofi Pasteur	Flublok	9 years and older	0.5 mL – prefilled syringe	IM (intramuscular)

## Cell Culture-Based Inactivated Influenza Vaccine, Trivalent (ccIIV3)

Manufacturer	Trade name	Age	Dose – Presentation	Route
Seqirus	Flucelvax	6 months and older	0.5 mL – prefilled syringe 0.5 mL – multi-dose vial	IM (intramuscular)

## Inactivated Influenza Vaccine, High Dose, Trivalent (HD-IIV3)

Manufacturer	Trade name	Age	Dose – Presentation	Route
Sanofi Pasteur	FluZone High-Dose	65 years and older	0.5 mL – prefilled syringe	IM (intramuscular)

## Inactivated Influenza Vaccine, Trivalent (IIV3)

Manufacturer	Trade name	Age	Dose – Presentation	Route
GlaxoSmithKline	Fluarix	6 months and older	0.5 mL – prefilled syringe	IM (intramuscular)
GlaxoSmithKline	FluLaval	6 months and older	0.5 mL – prefilled syringe	IM (intramuscular)
Seqirus	Afluria	6 through 35 months	0.25 mL – no option available <sup>4</sup>	IM (intramuscular)
Seqirus	Afluria	3 years and older	0.5 mL – prefilled syringe 0.5 mL – multi-dose vial <sup>5</sup>	IM (intramuscular)
Sanofi Pasteur	FluZone	6 months and older	0.5 mL – prefilled syringe 0.5 mL – single-dose vial 0.5 mL – multi-dose vial	IM (intramuscular)

## Live Attenuated Influenza Vaccine, Quadrivalent (LAIV3)

Manufacturer	Trade name	Age	Dose – Presentation	Route
AstraZeneca	FluMist	2 through 49 years	0.2 mL – prefilled intranasal sprayer; 0.1 mL in each nostril	Intranasal

Adapted from [CDC MMWR: Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2025–26 Influenza Season \(www.cdc.gov/mmwr/volumes/74/wr/mm7432a2.htm?s\\_cid=OS\\_mm7432a2\\_w\)](https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a2.htm?s_cid=OS_mm7432a2_w) (August 28, 2025; 74(32);500–507) Table 1.

<sup>1</sup> Make sure you are using the correct codes to enter doses into the Minnesota Immunization Information Connection (MIIC) by going to [MIIC Codes for Data Submission and Exchange \(www.health.state.mn.us/people/immunize/miic/data/codes.html\)](https://www.health.state.mn.us/people/immunize/miic/data/codes.html).

<sup>2</sup> An MDV formulation containing thimerosal might be available for the 2025–26 season. However, ACIP recommends only single-dose formulations that are free of thimerosal as a preservative.

<sup>3</sup> Recommended vaccination sites: adults and older children – deltoid muscle; infants and young children – anterolateral aspect of the thigh.

<sup>4</sup> The approved dose volume for Afluria is 0.25 mL for children aged 6 through 35 months however, 0.25-mL PFSs are no longer available and ACIP recommends only single-dose formulations that are free of thimerosal as a preservative. The Afluria 0.5-mL PFS presentation should be used only for persons aged ≥3 years.

<sup>5</sup> Although Afluria is licensed for administration with the PharmaJet Stratis needle-free injection system for persons age 18 through 64 years, it uses the presentation of a multi-dose vial containing thimerosal and is not recommended for use.